Cardiovascular Systems

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. Their primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications. Cardiovascular Systems develop solutions for the treatment of peripheral and coronary artery disease, to help physicians conquer calcium, one of the largest challenges when treating PAD and CAD.

Cardiovascular Systems Inc (NASDAQ: CSII) issued an update on financials citing the COVID-19 impact. The device maker says that the revenue for Q1 FY22 could be negatively affected by more than 10% from the anticipated level.

Cardiovascular Systems Expects COVID-19 Impact On Quarterly Revenue

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

Cardiovascular Systems (CSII) Down 6.6% Since Last Earnings Report: Can It Rebound?

The introduction of Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS in Canada will offer physicians an effective treatment option for patients with coronary artery diseases.

Cardiovascular Systems (CSII) Introduces Diamondback in Canada

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Canada have been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS). The first patients in Canada were treated by Sanjog Kalra, MD, Interventional Cardiologist and Cardiac Critical Care P

First Patients in Canada Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

Cardiovascular Systems' (CSII) CEO Scott Ward on Q4 2021 Results - Earnings Call Transcript

Strength in both coronary and peripheral segments drove Cardiovascular Systems' (CSII) revenues in the fiscal fourth quarter.

Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 17.65% and 2.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Reports Q4 Loss, Tops Revenue Estimates

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Reports Fiscal 2021 Fourth Quarter and Full Year Financial Results

Cardiovascular Systems, Inc. Reports Fiscal 2021 Fourth Quarter and Full Year Financial Results

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Cardiovascular Systems (CSII) Report Negative Earnings Next Week? What You Should Know

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to attend three investor conferences in August. Guggenheim MedTech Disruptors Summit Tuesday, August 10, 2021 Canaccord Genuity 41st Annual Growth Conference Wednesday, August 11, 2021 12:30 p.m. ET Webcast of present

Cardiovascular Systems, Inc. to Attend Three Investor Conferences in August

Shares of Cardiovascular Systems Inc. , a medical device company focused on treatments for vascular and coronary disease, tumbled 10.2% in afternoon trading, and has dropped 18.1% amid a four-day losing streak. Needham analyst Mike Matson noted that the Centers for Medicare & Medicaid Services' (CMS) proposed physician fee schedule for 2022 includes cuts of about 22% to office-based lab (OBL) payments for peripheral atherectomy.

Cardiovascular Systems stock drops after CMS proposes payment cuts, but Needham says buy on weakness

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO WEBCAST FISCAL 2021 FOURTH-QUARTER EARNINGS CONFERENCE CALL WEDNESDAY, AUGUST 4

Cardiovascular Systems, Inc. to Webcast Fiscal 2021 Fourth-Quarter Earnings Conference Call Wednesday, August 4

ST. PAUL, Minn.--(BUSINESS WIRE)--CSII at Raymond James Conf.

Cardiovascular Systems, Inc. to Participate at the Raymond James Human Health Innovations Conference

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES U.S. COMMERCIAL LAUNCH OF JADE OVER-THE-WIRE NON-COMPLIANT PERIPHERAL BALLOON CATHETERS

Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon Catheters

Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.

Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips

Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.

Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a real-world optical coherence tomography (OCT) imaging study of coronary OAS patients were released at EuroPCR 2021. The study conducted by Surendra Avula, MD, et al, at the University of Illinois, Chicago, was designed

New Study Demonstrates Exceptional Performance With Cardiovascular Systems' Diamondback 360® Coronary Orbital Atherectomy System (OAS) Dual Mode of Action

Increase in vaccinations and simultaneous decrease in COVID-19 hospitalizations in February and March result in improved procedure volumes for Cardiovascular Systems (CSII) in Q3.

Cardiovascular Systems (CSII) Q3 Loss Widens, Gross Margin Dips

Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q3 2021 Results - Earnings Call Transcript

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -50.00% and -0.25%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Reports Q3 Loss, Misses Revenue Estimates

ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q3 Earnings Release

Cardiovascular Systems, Inc. Reports Fiscal 2021 Third-Quarter Financial Results

ST. PAUL, Minn.--(BUSINESS WIRE)--JOURNAL OF MEDICAL ECONOMICS ARTICLE DEMONSTRATES ECONOMIC BENEFITS OF CARDIOVASCULAR SYSTEMS ORBITAL ATHERECTOMY

Journal of Medical Economics Article Demonstrates Economic Benefits of Cardiovascular Systems Orbital Atherectomy in the Treatment of Peripheral Artery Disease (PAD)

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the BofA Securities 2021 Health Care Conference on May 11th. A webcast of the presentation will be made available on CSI's website. BofA Securities 2021 Health Care Conference

Cardiovascular Systems, Inc. to Participate at BofA Securities 2021 Health Care Conference

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 third-quarter conference call on Thursday, May 6, 2021, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal third quarter ended March 31, 2021, and its financial outlook. CSI will issue a post-market earnings release prior to the call on May 6, 2021. To access the live webcast, go to the events section of CSI's investor relations website

Cardiovascular Systems, Inc. to Webcast Fiscal 2021 Third-Quarter Earnings Conference Call Thursday, May 6

Cardiovascular Systems' (CSII) investment in CarePICS will advance patient access to the suitable treatment at the right time, thereby leading to improved care and reduced amputations.

News for Cardiovascular Systems Stock (CSII)